CHM Cannabis
Home > Boards > Free Zone > All Fundamentals > $Pistol Pete$, $Mick$ & Friends Stock Picks /news, DD and charts

VRTHF QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TPX Member Profile
Followed By 532
Posts 34,219
Boards Moderated 5
Alias Born 10/24/13
160x600 placeholder
TPX   Thursday, 03/08/18 10:29:30 AM
Re: None
Post # of 191990 
VRTHF QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Inks MOU with BioCan Technologies

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has entered into a Memorandum of Understanding (“MOU”) with BioCan Technologies Inc. of Calgary, Alberta to collaborate exclusively to conduct additional investigations of cannabis strains being developed by Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”). Optimizing the genetics of the cannabis plants for scientific and clinical testing over the next two years is the company’s primary focus during the collaboration. Definitive agreements relating to the MOU are anticipated to be signed by July 31, 2018. “BioCan’s geneticists will help CTL scientists further develop proprietary strains that can produce consistent and optimal therapeutic effects in patients. We want to put in place a collaborative agreement with BioCan, which will outline this development work and related intellectual property as well as the approach to profit-sharing,” Veritas Pharma CEO, Dr. Lui Franciosi stated in the news release.

To view the full press release, visit

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical cannabis claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollars global markets. For more information, visit the company’s website at

Share Structure
Market Cap 16,840,847 03/01/2018

Authorized Shares Not Available
Outstanding Shares 38,714,590 12/06/2017

Veritas Pharma Signs Letter of Intent with 3 Carbon Extractions Inc.GlobeNewswire | 03/08/2018
Weekly Cannabis Report: Nasdaq Listing = 37% Pop In Share PriceSeeking Alpha | 03/05/2018
BioCan Technologies Signs Memorandum of Understanding with Veritas PharmaCANADA NEWSWIRE | 03/01/2018
Veritas Pharma Signs Memorandum of Understanding with BioCan TechnologiesGlobeNewswire | 02/28/2018
Weekly Cannabis Report: West Coast Competition IntensifiesSeeking Alpha | 02/26/2018
Veritas Pharma Completes Share Purchase Agreement of Sechelt Organic Marijuana Corp.GlobeNewswire | 02/23/2018
Veritas Pharma set to launch human trials of cannabis strain CTL-X in Puerto Rico next quarterSeeking Alpha | 02/21/2018
Veritas Pharma Provides Corporate Update on Q1 2018GlobeNewswire | 02/21/2018
Weekly Cannabis Report: A Clear Winner Has EmergedSeeking Alpha | 02/20/2018
Veritas Intends to Complete the 100% Takeover of Cannevert Therapeutics in Q1GlobeNewswire | 02/20/2018
Weekly Cannabis Report: The Only Bright Spot In The MarketSeeking Alpha | 02/12/2018
268 Marijuana Stocks: Learn From An Examination Of Event Dates For The Prior 52 WeeksSeeking Alpha | 02/07/2018

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist